ArticleThe Journal of clinical investigation1998
Role of interleukin 10 in specific immunotherapy.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 968 citations in OpenAlex.
- The association of allergic sensitization patterns in early childhood with disease manifestations and immunological reactivity at 10 years of age.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy.The Journal of allergy and clinical immunology · 2019Trial
- Evaluation of clinical and immunological responses: a 2-year follow-up study in children with allergic rhinitis due to house dust mite.Mediators of inflammation · 2013Trial
- Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children.Clinical and experimental immunology · 2010Trial
- T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.PLoS medicine · 2005Trial
- Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.Immunology · 2002Trial
- Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2.Cell reports. Medicine · 2026Article
- Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.Biomedicines · 2026Review
- The Role and Safety of Aluminum Adjuvants in Childhood Vaccines.Pediatrics · 2026Review
- Recombinant Hypoallergenic Cat Allergy Vaccines.Allergy · 2025Article
- Trends and hotspots on hymenoptera venom immunotherapy: a bibliometric and visualized analysis of research from 2014 to 2024.Frontiers in immunology · 2025Review
- The Role of Regulatory B Lymphocytes in Allergic Diseases.Biomedicines · 2024Review
- IgE versus IgG and IgA: Differential roles of allergen-specific antibodies in sensitization, tolerization, and treatment of allergies.Immunological reviews · 2024Review
- The role of regulatory B cells in immune regulation and childhood allergic asthma.Molecular and cellular pediatrics · 2024Review
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- Long-term tolerance and efficacy of venom immunotherapy after an episode of Crohn's disease and ankylosing spondylitis after up-dosing.Allergologie select · 2024Article
- Alteration of Immunoregulatory Patterns and Survival Advantage of Key Cell Types in Food Allergic Children.Cells · 2023Article
- Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives.Life (Basel, Switzerland) · 2023Review
- Peptide immunotherapy for aeroallergens.Allergy and asthma proceedings · 2023Article
- Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation.Journal of personalized medicine · 2023Review
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The induction of allergen-specific anergy in peripheral T cells represents a key step in specific immunotherapy (SIT). Here we demonstrate that the anergic state results from increased IL-10 production. In bee venom (BV)-SIT the specific proliferative and cytokine responses against the main allergen, the phospholipase A2 (PLA), and T cell epitope-containing PLA peptides were significantly suppressed after 7 d of treatment. Simultaneously, the production of IL-10 increased during BV-SIT. After 28 d of BV-SIT the anergic state was established. Intracytoplasmic cytokine staining of PBMC combined with surface marker detection revealed that IL-10 was produced initially by activated CD4(+)CD25(+), allergen-specific T cells, and followed by B cells and monocytes. Neutralization of IL-10 in PBMC fully reconstituted the specific proliferative and cytokine responses. A similar state of IL-10-associated T cell anergy, as induced in BV-SIT, was found in hyperimmune individuals who recently had received multiple bee stings. The addition of IL-10 to soluble CD40 ligand IL-4-stimulated PBMC or purified B cells inhibited the PLA-specific and total IgE and enhanced the IgG4 formation. Accordingly, increased IL-10 production by SIT causes specific anergy in peripheral T cells, and regulates specific IgE and IgG4 production toward normal IgG4-related immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.